



News Updates: January 30, 2014

Compulsory License/Patents

Publication: Business Standard

Edition: National

Date: January 30, 2014

Headline: [Protecting patents: India worst in world](#)

Synopsis: Despite the current decade being called India's "decade of innovation", the country has been ranked at the bottom of the list of 25 countries in terms of its intellectual property (IP) environment. According to the 2014 International Intellectual Property (IP) Index by the US Chamber of Commerce's Global Intellectual Property Center (GIPC), India's percentage score has fallen from 25 per cent in 2012 to 23 per cent. "The continued use of compulsory licences, patent revocations, and weak legislative and enforcement mechanisms raise serious concerns about India's commitment to promote innovation and protect creators," the report said.

Publication: The Financial Express

Edition: National

Date: January 30, 2014

Headline: [India ranked at the bottom of Intellectual Property Index](#)

Synopsis: In the second consecutive year, India has been ranked at the bottom of 25 countries in terms of protection and enforcement of intellectual property practices, a US Chamber of Commerce report said today. India has been a low seven point out of a maximum 30, with the United States topping the Intellectual Property (IP) index with 28.5 per cent. A report by the Global Intellectual Property Center (GIPC) of the US Chamber of Commerce maps the IP environment of 25 countries from around the world utilising 30 factors, which are indicative of an IP environments that fosters growth and development.

Publication: Financial Chronicle

Edition: Online

Date: January 29, 2014

Headline: [Merck and Bristol settle lawsuit with Aurobindo](#)

Synopsis: Drug making multinationals Merck Sharp & Dohme along with Bristol Myers Squibb have settled a law suit with Indian generics player Aurobindo Pharma which wanted to sell the copy cat version of their drug before the patent expires. The law suit was on at the New Jersey federal court. However, the terms of the settlement have not been made public yet. "We respect a product patent and so will not push for launching it before the product expires. The patent would expire in 2015. All our products are important for us and in Efavirenz (the active ingredient of the drug) there would have been lesser players," said a spokesperson of Aurobindo Pharma.

Drug regulation/FDA

Publication: The Hindu Business Line

Edition: National

Date: January 29, 2014

Headline: [UK drug regulator gives clean chit to Ranbaxy](#)

Synopsis: The UK drug regulator has given a clean chit to Ranbaxy Laboratories' medicines, even as the US Food and Drug Administration (FDA) last week banned medicines being manufactured at the company's

Toansa plant in Punjab. "There is no evidence that medicines in the UK are defective so people should continue to take their medicines accordingly," a spokesperson of the Medicines and Healthcare Products Regulatory Agency (MHRA) said. However, the spokesperson added the agency is working with other international regulatory partners as well as the regulator of the EU to determine whether the US FDA findings have any implications for the UK.

Publication: The Economic Times

Edition: Online

Date: January 29, 2014

Headline: [EU, UK evaluating FDA findings on Ranbaxy's Toansa facility](#)

Synopsis: Days after the US Food and Drug Administration banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU and the UK have said they are evaluating the FDA inspection findings to assess if deviations from GMP have any implication in their markets.

M&A

Publication: Mint

Edition: National

Date: January 30, 2014

Headline: [2014 likely to see more M&A deals by global investors: KPMG study](#)

Synopsis: The world's largest companies could be hungrier for mergers and acquisitions (M&A) in 2014 compared with a year ago, said a report released on Wednesday.

In India, M&A activity may pick up if the economy shows signs of revival and the global economy remains stable, according to the Global M&A Predictor study by KPMG, an audit and consultancy firm. The report covers the world by sector and region and is produced twice a year, using data comprising 1,000 of the largest public companies, excluding financial services and property sectors, in the world by market capitalization.

General Industry News

Publication: Business Today

Edition: Online

Date: January 29, 2014

Authored Article - Deepak Wadhwa, Assistant Manager - Operations in the health-care analytics vertical of WNS Global Services)

Headline: [Expert speak: How Indian pharma companies can grow their business](#)

Synopsis: In the past few years, the Indian pharmaceutical Industry (IPI) has grown at nearly 12 to 15 per cent which is a tremendous pace of growth if we compare it to that of the US or European markets. No doubt the growth of the industry will continue to be in double digits and India may rank among the top five global pharma markets by 2030. But it is also becoming difficult for domestic companies to survive in the current scenario. Along with small and mid-size firms, even a few big players have exited the business in the last five to seven years.

Publication: Business Standard (Smart Investor)

Edition: Online

Date: January 30, 2014

Headline: [If I follow US standards, I will have to shut almost all drug facilities: G N Singh](#)

Synopsis: At a time India-made medicines appear to be losing sheen the world over, the country's top regulator, the Drug Controller General of India (DCGI), is struggling to ensure quality of drugs in the domestic market. Faced with criticism on many fronts, DCGI feels the India market might not be ready to follow global standards and the Indian industry might even collapse with the stringent norms followed elsewhere. Talking

specifically on Ranbaxy, Drug Controller General G N Singh spoke to Sushmi Dey that the DCGI can become the toughest watchdog when it comes to quality and even ban the company from the India market if it fails further in compliance.

Publication: Business Standard

Edition: Online

Date: January 30, 2014

Headline: [AstraZeneca to shut down R&D site in Bangalore](#)

Synopsis: AstraZeneca, the global pharmaceutical major, on Wednesday said that it will close its research and development site in Bangalore later this year. The 'Avishkar R&D Site', employing 168 researchers, was one of the critical centres of AstraZeneca and was involved in the pharmaceutical development and drug discovery research into neglected tropical disease, tuberculosis (TB) and malaria.

Similar reports in

The Financial Express - [AstraZeneca to close down Bangalore R&D centre, 168 employees may get the axe](#)

Publication: Business Standard

Edition: Online

Date: January 30, 2014

Headline: [Dubai-based DM Healthcare set to make Rs 300-cr hospital acquisitions](#)

Synopsis: Dubai-based hospital group DM Healthcare is in talks to acquire a mid-sized hospital here in India. It is also in talks with hospitals in Hyderabad and Bangalore to expand its business in India inorganically